Clinical trial
Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal…
NCT00328653 · Santen SAS, Industry · Completed
Key facts
| NCT number | NCT00328653 |
|---|---|
| Title | Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC) |
| Official title | Phase II/III, Multicenter, Double-Masked, Randomized, Parallel Group, Dose Ranging, Controlled Trial of Efficacy and Tolerance of Nova22007 (Cyclosporine A [CSA] 0.05% & 0.1% Ophthalmic Cationic Emulsion) Versus Vehicle in Patients With VKC |
| Lead sponsor | Santen SAS, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Conjunctivitis, Vernal |
| Intervention type | Drug |
| Interventions | Cyclosporine NOVA22007 0.05%, Cyclosporine NOVA22007 0.1%, Vehicle |
| Enrollment | 118 |
| Start date | May 1, 2006 |
| Primary completion | Feb 22, 2007 |
| First posted | May 22, 2006 |
| Last update posted | Dec 14, 2021 |
| Countries | France |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: